What were the key agreements entered into by BeiGene around its IPO?

BeiGene entered into a Deposit Agreement with Citibank, N.A. for its American Depositary Shares (ADSs). Additionally, an amendment to its Second Amended and Restated Investors' Rights Agreement became effective, which modified the conditions for piggyback registration rights for shareholders, linking them to a minimum ownership of 4% of the company's outstanding ordinary shares.

How was the $10 million note with MSD resolved?

On February 8, 2016, the outstanding principal and interest on the $10 million senior note issued to Merck Sharp & Dohme Research GmbH (MSD) were automatically exchanged for 7,942,314 ordinary shares of BeiGene. This exchange was made at the initial public offering price of $1.85 per share.

What significant changes were made to the company's Articles of Association?

The company's Fourth Amended and Restated Memorandum and Articles of Association became effective upon the IPO closing. Key changes include eliminating preferred share references, authorizing a substantial increase in ordinary shares (9.5 billion) and a class of undesignated shares (500 million), implementing a three-class board structure, designating the courts of the Cayman Islands as the exclusive forum for certain legal actions, and establishing a provision for shareholders who initiate unsuccessful claims against the company to reimburse the company for legal costs.

Who were the new directors elected to the board?

Effective upon the IPO closing on February 8, 2016, Xiaodong Wang, Ph.D., the company's Founder and Chairman of the scientific advisory board, and Timothy Chen, a corporate executive with extensive experience in international business and technology, were elected to the Board of Directors.

ONC 8-K: Leadership Changes, Material Agreements & More

Summary

BeiGene, Ltd. (ONC) filed an 8-K on February 11, 2016, primarily to report on material definitive agreements and unregistered sales of equity securities in connection with its initial public offering (IPO). The company entered into a Deposit Agreement for its American Depositary Shares (ADSs) and an amendment to its Investors' Rights Agreement, which impacts piggyback registration rights. A significant event was the conversion of a $10 million senior note with Merck Sharp & Dohme Research GmbH (MSD) into approximately 7.9 million ordinary shares at the IPO price. Furthermore, the filing details the automatic conversion of preferred shares into ordinary shares upon the IPO's closing, stemming from warrant and option exercises that occurred prior to the IPO. The company also announced the election of two new directors, Xiaodong Wang, Ph.D. (Founder and Chairman of the Scientific Advisory Board) and Timothy Chen, a seasoned executive with extensive experience in Asia and globally. The company's Articles of Association were also restated, effective with the IPO closing, to reflect its status as a public company, including changes to share authorization, board structure, and forum selection for legal disputes.

Key Highlights

1BeiGene, Ltd. (ONC) completed its initial public offering (IPO) on February 8, 2016.
2A $10 million senior note with MSD was exchanged for approximately 7.94 million ordinary shares at the IPO price of $1.85 per share.
3The company entered into a Deposit Agreement for its American Depositary Shares (ADSs).
4An amendment to the Investors' Rights Agreement became effective, modifying piggyback registration rights based on share ownership thresholds.
5The company's Fourth Amended and Restated Memorandum and Articles of Association were updated to align with public company status, including an authorized share capital increase and a classified board structure.
6Xiaodong Wang, Ph.D., a key founder and scientific advisor, and Timothy Chen, a corporate executive, were elected to the Board of Directors.
7The filing discloses the conversion of warrants and options into 4.67 million ordinary shares prior to the IPO's closing.

BeOne Medicines Ltd. 8-K Report, Material Agreement (Feb 11, 2016)

Summary

Key Highlights

Frequently Asked Questions